A cost benefit analysis of BCG vaccination as a control measure against tuberculosis as compared to treatment of infectious cases
A cost benefit analysis of BCG vaccination as a control measure against tuberculosis as compared to treatment of infectious cases.
Indian Journal of T uberculosis, 22 (1).
Full text available as:
BCG vaccination as a measure of control
of Tuberculosis has been advocated particularly
for developing countries. A controlled study
conducted in South India suggests that BCG
vaccination would have an impact of only about
8 percent on the total tuberculosis expected
during 20-21 years.
|Uncontrolled Keywords:||BCG Vaccination, Tuberculosis, Control Measure, Infectious Cases, Tuberculosis Control Programme, South India, Cost Benefit Analysis, Cost of Treatment|
|Subjects:||Bacterial Infections and Mycoses > Bacterial Infections > Gram-Positive Bacterial Infections > Actinomycetales Infections > Mycobacterium Infections|
Health Care Economics and Organizations > Health Planning > National Health Programs
Therapeutics > Biological Therapy > Immunotherapy > Immunization > Immunotherapy, Active > Vaccination
Respiratory Tract Diseases > Respiratory Tract Infections > Tuberculosis, Pulmonary
Respiratory Tract Diseases > Lung Diseases > Tuberculosis, Pulmonary
-Journal Repositories > Indian Journal of Tuberculosis
Social Sciences > Economics
Health Care Economics and Organizations > Economics
Immunologic and Biological Factors > Biological Products > Vaccines > Bacterial Vaccines > Tuberculosis Vaccines > BCG Vaccine
|Deposited By:||Mrs Naina Pandita|
|Deposited On:||23 June 2006|
Archive Staff Only: edit this record